Fresenius Medical Care AG & Co. (Pref) (ETR:FME) received a €94.00 ($104.44) target price from Berenberg Bank in a research note issued to investors on Wednesday. The brokerage presently has a a “buy” rating on the stock.

Other equities research analysts have also issued reports about the stock. Morgan Stanley set a €97.00 ($107.78) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a report on Monday, August 8th. Goldman Sachs Group Inc. set a €94.00 ($104.44) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a report on Tuesday, June 28th. BNP Paribas set a €80.00 ($88.89) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “neutral” rating in a report on Wednesday, August 3rd. Nord/LB set a €93.00 ($103.33) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a report on Monday, August 8th. Finally, Societe Generale set a €90.00 ($100.00) price objective on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “neutral” rating in a report on Wednesday, August 3rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of €88.97 ($98.86).

Analyst Recommendations for Fresenius Medical Care AG & Co. (Pref) (ETR:FME)

Shares of Fresenius Medical Care AG & Co. (ETR:FME) opened at 79.30 on Wednesday. The company has a market capitalization of €24.25 billion and a price-to-earnings ratio of 21.98. The firm’s 50-day moving average is €80.85 and its 200 day moving average is €77.97. Fresenius Medical Care AG & Co. has a 12 month low of €67.50 and a 12 month high of €85.52.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/fresenius-medical-care-ag-co-pref-fme-given-a-94-00-price-target-by-berenberg-bank-analysts.html

About Fresenius Medical Care AG & Co. (Pref)

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Receive News & Ratings for Fresenius Medical Care AG & Co. (Pref) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. (Pref) and related companies with MarketBeat.com's FREE daily email newsletter.